Drug Approval | September 04, 2025
Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Subscribe To Our Newsletter & Stay Updated
